Analysts at RBC Capital Kept the Same their Buy rating for Aurinia Pharmaceuticals (AUPH) with $11 Price Objective; Biogen (BIIB) SI Decreased By 3.87% – The Hi New Ulm

Analysts at RBC Capital Kept the Same their Buy rating for Aurinia Pharmaceuticals (AUPH) with $11 Price Objective; Biogen (BIIB) SI Decreased By 3.87%  The Hi New UlmIn an analyst note revealed on today, RBC Capital kept their Buy rating on Aurinia Pharmaceuticals (NASDAQ:AUPH)’s stock. The price target gives a potential …

Read More